Abstract 278P
Background
Radical chemoradiation (CTRT) is the standard of care in locally advanced head and neck cancer (LAHNC). For mitigating the normal tissue toxicity, many techniques have been explored and utilized, including IMRT and adaptive radiotherapy (ART). Significant anatomical variations occur during CTRT due to weight loss and tumor and normal tissue changes. In the present study, serial changes in parotid volumes were assessed with weekly scans along with dosimetric correlation.
Methods
This prospective, single-institutional study, included 12 patients with LA HNC receiving CTRT. All underwent CT simulation (CT sim) followed by weekly rescans from week 1 to 6. Target volumes and organs at risk, including right & left parotids (RP & LP) were recontoured in all rescans after fusion with the CT sim. Dose overlay was done in each rescan to generate a hybrid plan to study corresponding dosimetric variations. Volume changes in parotids were reported as percentage change from the baseline.
Results
In CT sim, right parotid volumes (RPV) ranged from 15.7 - 44.2 cc (mean - 24.1 SD – 7.9) and left parotid volume (LPV) from 12.2 - 47.1 cm3 (mean 22.8, SD -9.9). Mean % reduction in RPV in week 1, 2, 3, 4, 5 and 6 were 14.2% (p=0.003), 17.1% (p=0.007), 21.8% (p < 0.001), 25.6% (p < 0.001), 30% (p < 0.001), 32.1% (p < 0.001) respectively. Mean % reduction in LPV in week 1, 2, 3, 4, 5 and 6 were 8.9% (p=0.016), 14.5% (p=0.012), 17.7% (p=0.001), 20.1% (p=0.002), 24.9% (p < 0.001), 28.9% (p < 0.001) respectively. LP D mean showed a significant increase in week 3 (4.6% from baseline, p=0.019) and week 6 (7.6% from baseline, p=0.034). Both parotids showed a significant reduction in V26 Gy with 12.3%, 15.1%, 18.9%, 22.9%, 25.7%, 27.0%, respectively, from week 1 to 6 in RP and 7.3%, 15.7%, 13.8%, 16.8%, 20.8%, 24.1%, respectively, in LP.
Conclusions
Parotid volume shrinkage started from the 1st week. At the end of CTRT, there was 30-32% reduction in volume. V26 Gy of both parotids showed significant reduction during CTRT. Studies focusing on parotid volume changes shows wide variations in volume reduction ranging from 13% to 50% at the end of treatment. These parotid volume changes during RT need to be incorporated while doing ART in LAHNC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Uttarakhand.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session